US EditionWest Pharmaceutical Lifts Full-Year Forecast After Strong Q2 Performance
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
West Pharmaceutical Lifts Full-Year Forecast After Strong Q2 Performance
EXTON, PA — West Pharmaceutical Services, Inc. (NYSE: WST) raised its full-year revenue and earnings guidance following a better-than-expected second quarter, driven by strong demand for high-value product components and improved customer ordering trends. Net sales for Q2 2025 reached $766.5 million, up 9.2% from the same period last year, with organic growth at 6.8%. Adjusted diluted earnings per share climbed to $1.84, compared to $1.52 in the…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
